Previous 10 | Next 10 |
Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs, initial data to be shared by year end June 30, 2022 cash ...
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
Shares of Kymera Therapeutics ( NASDAQ: KYMR ) had gained 15.6% to $26.30 in Tuesday mid-day trading after Goldman Sachs research initiated the clinical-stage biopharmaceutical company with a buy rating, citing an attractive risk reward. Goldman Sachs analysts Chris Shib...
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on Au...
WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its ...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Kymera Therapeutics (NASDAQ:KYMR) said it dosed the first patients in separate phase 1 trials of KT-333 and KT-413. The Watertown, Mass.-based company said one phase 1 trial is evaluating KT-333 adult patients with relapsed/refractory liquid and solid tumors, including T cell lymphomas and le...
Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413 PR Newswire KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and so...
Clinical-stage biotech Kymera Therapeutics (NASDAQ:KYMR) is trading higher in the morning hours Wednesday after the company announced that the FDA granted its Orphan Drug Designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL). With its orphan drug designation, the FDA ai...
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administrat...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...